Pancreatic cancer: genetics, disease progression, therapeutic resistance and treatment strategies

Abstract

Pancreatic cancer is a deadly disease and the third-highest cause of cancer-related deaths in the United States. It has a very low five-year survival rate (< 5%) in the United States as well as in the world (about 9%). The current gemcitabine-based therapy soon becomes ineffective because treatment resistance and surgical resection also provides only selective benefit. Signature mutations in pancreatic cancer confer chemoresistance by deregulating the cell cycle and promoting anti-apoptotic mechanisms. The stroma-rich tumor microenvironment impairs drug delivery and promotes tumor-specific immune escape. All these factors render the current treatment incompetent and prompt an urgent need for new, improved therapy. In this review, we have discussed the genetics of pancreatic cancer and its role in tumor evolution and treatment resistance. We have also evaluated new treatment strategies for pancreatic cancer, like targeted therapy and immunotherapy.

Keywords

Pancreatic cancer / signature mutations / gemcitabine / desmoplasia / therapeutic resistance / immunotherapy

References

[1] Siegel RL,Jemal A.Cancer statistics, 2020.CA Cancer J Clin2020;70:7-30

[2] Fokas E,Gordon-Weeks A,McKenna WG.Pancreatic ductal adenocarcinoma: from genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic.Biochim Biophys Acta2015;1855:61-82

[3] Garrido-Laguna I.Pancreatic cancer: from state-of-the-art treatments to promising novel therapies.Nat Rev Clin Oncol2015;12:319-34

[4] Kleeff J,Apte M.Pancreatic cancer.Nat Rev Dis Primers2016;2:16022

[5] Adamska A,Falasca M.Pancreatic ductal adenocarcinoma: current and evolving therapies.Int J Mol Sci2017;18:1338 PMCID:PMC5535831

[6] Lüttges J,Klöppel G.Where and when does pancreatic carcinoma start?.Med Klin (Munich)2004;99:191-5

[7] Bardeesy N.Pancreatic cancer biology and genetics.Nat Rev Cancer2002;2:897-909

[8] Bellizzi AM.Pancreatic pathology: a practical review.Lab Med2009;40:417-26.1

[9] Ro C,Yu VE.Pancreatic neuroendocrine tumors: biology, diagnosis,and treatment.Chin J Cancer2013;32:312-24 PMCID:PMC3845620

[10] Salem AA.Pancreatic cancer: a critical review of dietary risk.Nutr Res2018;52:1-13

[11] Gupta S,Holly EA.Risk of pancreatic cancer by alcohol dose, duration, and pattern of consumption, including binge drinking: a population-based study.Cancer Causes Control2010;21:1047-59 PMCID:PMC2883092

[12] Becker AE,Frucht H.Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection.World J Gastroenterol2014;20:11182-98 PMCID:PMC4145757

[13] Wörmann SM.Risk factors and therapeutic targets in pancreatic cancer.Front Oncol2013;3:282 PMCID:PMC3831165

[14] Bliss LA,Yang CJ.Outcomes in operative management of pancreatic cancer.J Surg Oncol2014;110:592-8

[15] Heinemann V.Gemcitabine: progress in the treatment of pancreatic cancer.Oncology2001;60:8-18

[16] Jones S,Parsons DW.Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.Science2008;321:1801-6 PMCID:PMC2848990

[17] Mimeault M,Sasson AA.Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies.Pancreas2005;31:301-16

[18] Shimizu T,Papadopoulos KP.The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.Clin Cancer Res2012;18:2316-25

[19] Moskaluk CA,Kern SE.p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma.Cancer Res1997;57:2140-3

[20] Karanikas M,Chasan ZT.Pancreatic cancer from molecular pathways to treatment opinion.J Cancer2016;7:1328-39 PMCID:PMC4934041

[21] Serrano M,McCurrach ME,Lowe SW.Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;88:593-602.

[22] Brookes S,Ruas M.INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence.EMBO J2002;21:2936-45 PMCID:PMC126048

[23] Rozenblum E,Goggins M.Tumor-suppressive pathways in pancreatic carcinoma.Cancer Res1997;57:1731-4

[24] Nakashima H,Yamaguchi H.Nuclear factor-kappaB contributes to hedgehog signaling pathway activation through sonic hedgehog induction in pancreatic cancer.Cancer Res2006;66:7041-9

[25] Ling J,Zhao R.KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.Cancer Cell2012;21:105-20 PMCID:PMC3360958

[26] Gu D,Xie J.Deciphering the role of hedgehog signaling in pancreatic cancer.J Biomed Res2016;30:353-60 PMCID:PMC5044707

[27] Tascilar M,Rosty C.The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma.Clin Cancer Res2021;7:4115-21

[28] Lowery MA,Jordan EJ.Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms.J Natl Cancer Inst2018;110:1067-74 PMCID:PMC6186514

[29] Wong W,Safyan RA,Manji GA.BRCA mutations in pancreas cancer: spectrum, current management, challenges and future prospects.Cancer Manag Res2020;12:2731-42 PMCID:PMC7185320

[30] Cheng JQ,Klein WM.Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA.Proc Natl Acad Sci U S A1996;93:3636-41 PMCID:PMC39663

[31] Ruggeri BA,Wood M,Testa JR.Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas.Mol Carcinog1998;21:81-6

[32] Payne SN,Tran NH.PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors.Oncogenesis2015;4:e169 PMCID:PMC4632089

[33] Sivaram N,Han HV.Tumor-intrinsic PIK3CA represses tumor immunogenecity in a model of pancreatic cancer.J Clin Invest2019;129:3264-76 PMCID:PMC6668699

[34] Papke B.Drugging RAS: know the enemy.Science2017;355:1158-63

[35] Buscail L,Cordelier P.Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer.Nat Rev Gastroenterol Hepatol2020;17:153-68

[36] Chambard JC,Pouysségur J.ERK implication in cell cycle regulation.Biochim Biophys Acta2007;1773:1299-310

[37] Huang L,Zhang SY,Chang H.Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.Cancer Res1996;56:1137-41

[38] Gerdes B,Ziegler A.p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, an Rb.Ann Surg2002;235:51-9 PMCID:PMC1422395

[39] Schmitt CA,Yang M.A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy.Cell2002;109:335-46

[40] Morton JP,Karim SA.Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer.Proc Natl Acad Sci U S A2010;107:246-51 PMCID:PMC2806749

[41] Kim MP,Deng J.Oncogenic.KRASrecruits an expansive transcriptional network through mutant p53 to drive pancreatic cancer metastasis. Cancer Discov 2021

[42] Weissmueller S,Saborowski M.Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling.Cell2014;157:382-94 PMCID:PMC4001090

[43] Malkoski SP.Two sides of the story?.FEBS Lett2012;586:1984-92 PMCID:PMC3285395

[44] Zhao M,Deng CX.The role of TGF-β/SMAD4 signaling in cancer.Int J Biol Sci2018;14:111-23 PMCID:PMC5821033

[45] Lecanda J,D'Aquino-Ardalan C.TGFbeta prevents proteasomal degradation of the cyclin-dependent kinase inhibitor p27kip1 for cell cycle arrest.Cell Cycle2009;8:742-56

[46] Adamska A,Emmanouilidi A.Molecular and cellular mechanisms of chemoresistance in pancreatic cancer.Adv Biol Regul2018;68:77-87

[47] Mackey JR,Selner M.Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines.Cancer Res1998;58:4349-57

[48] Sousa Cavalcante L, Monteiro G. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer.Eur J Pharmacol2014;741:8-16

[49] Binenbaum Y,Gil Z.Gemcitabine resistance in pancreatic ductal adenocarcinoma.Drug Resist Updat2015;23:55-68

[50] Hung SW,Govindarajan R.Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.Cancer Lett2012;320:138-49 PMCID:PMC3569094

[51] Skrypek N,Hebbar M,van Seuningen I.The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.Oncogene2013;32:1714-23 PMCID:PMC3936121

[52] Schinkel AH.Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview.Adv Drug Deliv Rev2003;55:3-29

[53] Maréchal R,Lai R.Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma.Cancer2010;116:5200-6

[54] Bergman AM,Ruiz van Haperen VW.In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant.Cancer Res2005;65:9510-6

[55] Davidson JD,Flagella M,Gelbert LM.An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.Cancer Res2004;64:3761-6

[56] Asano T,Zhu J,Abbruzzese JL.The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells.Oncogene2004;23:8571-80

[57] Singh K. Therapeutic targeting of deregulated cell cycle and UPR in pancreatic cancer by tetrandrine. PhD, Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center at Shreveport, ProQuest, 2018.

[58] Ebrahimi S,Shahidsales S.Targeting the Akt/PI3K signaling pathway as a potential therapeutic strategy for the treatment of pancreatic cancer.Curr Med Chem2017;24:1321-31

[59] Yamamoto S,Hoshida Y.Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma.Clin Cancer Res2004;10:2846-50

[60] Parsons CM,Bowles TL,Bold RJ.The role of Akt activation in the response to chemotherapy in pancreatic cancer.Anticancer Res2010;30:3279-89 PMCID:PMC4557882

[61] Ng SSW,Chow S.Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells.Cancer Res2000;60:5451-5

[62] Xie D.Pancreatic cancer stromal biology and therapy.Genes Dis2015;2:133-43 PMCID:PMC4476547

[63] Waghray M,di Magliano MP.Deciphering the role of stroma in pancreatic cancer.Curr Opin Gastroenterol2013;29:537-43 PMCID:PMC4112589

[64] Nielsen MF,Detlefsen S.Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells.World J Gastroenterol2016;22:2678-700 PMCID:PMC4777992

[65] Walter K,Hong SM.Overexpression of smoothened activates the sonic hedgehog signaling pathway in pancreatic cancer-associated fibroblasts.Clin Cancer Res2010;16:1781-9 PMCID:PMC2846609

[66] Gore J.Pancreatic cancer stroma: friend or foe?.Cancer Cell2014;25:711-2 PMCID:PMC4821630

[67] Li H,Chen SW.Cancer-associated fibroblasts provide a suitable microenvironment for tumor development and progression in oral tongue squamous cancer.J Transl Med2015;13:198 PMCID:PMC4475624

[68] Heldin CH,Pietras K.High interstitial fluid pressure - an obstacle in cancer therapy.Nat Rev Cancer2004;4:806-13

[69] Liang C,Meng Q.Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going.Exp Mol Med2017;49:e406 PMCID:PMC5750480

[70] Kozono S,Eguchi D.Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells.Cancer Res2013;73:2345-56

[71] Jacobetz MA,Neesse A.Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer.Gut2013;62:112-20 PMCID:PMC3551211

[72] Provenzano PP,Chang AE,Von Hoff DD.Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.Cancer Cell2012;21:418-29 PMCID:PMC3371414

[73] Hingorani SR,Beck JT.Phase Ib study of PEGylated recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer.Clin Cancer Res2016;22:2848-54 PMCID:PMC7787348

[74] Alvarez R,Garcia-Garcia E.Stromal disrupting effects of nab-paclitaxel in pancreatic cancer.Br J Cancer2013;109:926-33 PMCID:PMC3749580

[75] Von Hoff DD,Arena FP.Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.N Engl J Med2013;369:1691-703 PMCID:PMC4631139

[76] Hotz HG,Hotz B.Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth.J Gastrointest Surg2001;5:131-8

[77] Olive KP,Davidson CJ.Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.Science2009;324:1457-61 PMCID:PMC2998180

[78] Olivares O,Gouirand V.Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions.Nat Commun2017;8:16031 PMCID:PMC5504351

[79] Hosein AN,Maitra A.Pancreatic cancer stroma: an update on therapeutic targeting strategies.Nat Rev Gastroenterol Hepatol2020;17:487-505 PMCID:PMC8284850

[80] Vennin C,Warren SC.Australian Pancreatic Cancer Genome Initiative (APGI)Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis.Sci Transl Med2017;9:eaai8504 PMCID:PMC5777504

[81] Jiang H,Knolhoff BL.Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.Nat Med2016;22:851-60 PMCID:PMC4935930

[82] Aguilera KY,Du W.Inhibition of discoidin domain receptor 1 reduces collagen-mediated tumorigenicity in pancreatic ductal adenocarcinoma.Mol Cancer Ther2017;16:2473-85 PMCID:PMC5669827

[83] Boucher MJ,Vachon PH,Lainé J.MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells.J Cell Biochem2000;79:355-69.

[84] Wang M,Dong X.pERK1/2 silencing sensitizes pancreatic cancer BXPC-3 cell to gemcitabine-induced apoptosis via regulating Bax and Bcl-2 expression.World J Surg Oncol2015;13:66 PMCID:PMC4337256

[85] Karimian A,Yousefi B.Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage.DNA Repair (Amst)2016;42:63-71

[86] Chien W,Sun QY.Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells.Oncotarget2014;5:4881-94 PMCID:PMC4148107

[87] Ma Y.The role of the unfolded protein response in tumour development: friend or foe?.Nat Rev Cancer2004;4:966-77

[88] Yousefi H,Keshavarz-Fathi M,Rezaei N.Immunotherapy of cancers comes of age.Expert Rev Clin Immunol2017;13:1001-15

[89] Patel SP.PD-L1 expression as a predictive biomarker in cancer immunotherapy.Mol Cancer Ther2015;14:847-56

[90] Beatty GL,Fishman MP.CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.Science2011;331:1612-6 PMCID:PMC3406187

[91] De Monte L,Tassi E.Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer.J Exp Med2011;208:469-78 PMCID:PMC3058573

[92] Fukunaga A,Cho Y.CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma.Pancreas2004;28:e26-31

[93] Schizas D,Kole C.Immunotherapy for pancreatic cancer: a 2020 update.Cancer Treat Rev2020;86:102016

[94] Royal RE,Turner K.Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma.J Immunother2010;33:828-33 PMCID:PMC7322622

[95] Kalyan A,Mohindra NA.Ipilimumab and gemcitabine for advanced pancreas cancer: a phase Ib study.J Clin Oncol2016;34:e15747

[96] Luo W,Luo W.Novel therapeutic strategies and perspectives for metastatic pancreatic cancer: vaccine therapy is more than just a theory.Cancer Cell Int2020;20:66 PMCID:PMC7057654

[97] Miyazawa M,Maguchi H.Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients.Int J Cancer2017;140:973-82

[98] Mucciolo G,Scagliotti A,Novelli F.The dark side of immunotherapy: pancreatic cancer.Cancer Drug Resist2020;3:491-520

[99] Le DT,Uram JN.Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.J Immunother2013;36:382-9 PMCID:PMC3779664

[100] Holter S,Dodd A.Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma.J Clin Oncol2015;33:3124-9

[101] Salo-Mullen EE,Kelsen DP.Identification of germline genetic mutations in patients with pancreatic cancer.Cancer2015;121:4382-8 PMCID:PMC5193099

[102] Waddell N,Patch AM.Australian Pancreatic Cancer Genome InitiativeWhole genomes redefine the mutational landscape of pancreatic cancer.Nature2015;518:495-501 PMCID:PMC4523082

[103] Lord CJ.BRCAness revisited.Nat Rev Cancer2016;16:110-20

[104] Gupta M,Fountzilas C.Poly(ADP-Ribose) Polymerase inhibitors in pancreatic cancer: a new treatment paradigms and future implications.Cancers (Basel)2019;11:1980 PMCID:PMC6966572

[105] Golan T,Reni M.Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.N Engl J Med2019;381:317-27 PMCID:PMC6810605

[106] Zhu H,Xu J.PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications.Mol Cancer2020;19:49 PMCID:PMC7053129

[107] Leroux C.Targeted therapies for pancreatic cancer: overview of current treatments and new opportunities for personalized oncology.Cancers (Basel)2021;13:799 PMCID:PMC7918504

[108] Lawrence TS,Hahn TM,Shewach D.Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine.International Journal of Radiation Oncology*Biology*Physics1996;34:867-72

[109] Doyle TH,McKenna WG.The clinical implications of gemcitabine radiosensitization.Clin Cancer Res2001;7:226-8

[110] Tuli R,Reyes J.Radiosensitization of pancreatic cancer cells in vitro and in vivo through poly (ADP-ribose) polymerase inhibition with ABT-888.Transl Oncol2014:439-45 PMCID:PMC4145354

[111] Jiang Y,Li Y.PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer.Int J Cancer2019;144:1092-103 PMCID:PMC6320711

[112] Waissi W,Jung M.Radiosensitizing pancreatic cancer with PARP inhibitor and gemcitabine: an in vivo and a whole-transcriptome analysis after proton or photon irradiation.Cancers (Basel)2021;13:527 PMCID:PMC7866541

[113] Öhlund D,Tuveson D.Fibroblast heterogeneity in the cancer wound.J Exp Med2014;211:1503-23 PMCID:PMC4113948

[114] Fiori ME,Villanova L,Stassi G.Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance.Mol Cancer2019;18:70 PMCID:PMC6441236

[115] Domen A,Zanivan S.Cancer-associated fibroblasts as a common orchestrator of therapy resistance in lung and pancreatic cancer.Cancers (Basel)2021;13:987 PMCID:PMC7956441

[116] Wu Q,Zhang J.Functions of pancreatic stellate cell-derived soluble factors in the microenvironment of pancreatic ductal carcinoma.Oncotarget2017;8:102721-38 PMCID:PMC5731993

[117] Ene-Obong A,Watt J.Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma.Gastroenterology2013;145:1121-32 PMCID:PMC3896919

[118] Kumar V,Marvel D.Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors.Cancer Cell2017;32:654-68.e5 PMCID:PMC5827952

[119] Francescone R,Franco-Barraza J.Netrin G1 promotes pancreatic tumorigenesis through cancer-associated fibroblast-driven nutritional support and immunosuppression.Cancer Discov2021;11:446-79 PMCID:PMC7858242

[120] Cohen SJ,Palazzo I.Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma.Pancreas2008;37:154-8

[121] Sunami Y,Kleeff J.Targeting and reprograming cancer-associated fibroblasts and the tumor microenvironment in pancreatic cancer.Cancers (Basel)2021;13:697 PMCID:PMC7915918

[122] Zhang Y,Jung M.Macropinocytosis in cancer-associated fibroblasts is dependent on CaMKK2/ARHGEF2 signaling and functions to support tumor and stromal cell fitness.Cancer Discov2021;11:1808-25 PMCID:PMC8292164

[123] Davidson SM,Keibler MA.Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors.Nat Med2017;23:235-41 PMCID:PMC5407288

[124] Neoptolemos JP,Michl P,Greenhalf W.Therapeutic developments in pancreatic cancer: current and future perspectives.Nat Rev Gastroenterol Hepatol2018;15:333-48

[125] Conroy T,Ychou M.Groupe Tumeurs Digestives of UnicancerPRODIGE IntergroupFOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.N Engl J Med2011;364:1817-25